BSL — Raffles Medical Income Statement
0.000.00%
Last trade - 00:00
- SG$1.64bn
- SG$1.56bn
- SG$706.92m
- 77
- 41
- 46
- 57
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 522 | 568 | 724 | 823 | 707 |
Cost of Revenue | |||||
Gross Profit | 411 | 432 | 581 | 731 | 616 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 446 | 480 | 602 | 627 | 591 |
Operating Profit | 76.2 | 88.4 | 121 | 195 | 116 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 75.9 | 84.4 | 116 | 191 | 119 |
Provision for Income Taxes | |||||
Net Income After Taxes | 60.5 | 64.7 | 83.7 | 143 | 91.1 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 60.3 | 65.9 | 84.2 | 143 | 90.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 60.3 | 65.9 | 84.2 | 143 | 90.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.033 | 0.038 | 0.044 | 0.082 | 0.045 |
Dividends per Share | |||||
Special Dividends per Share |